Articles On Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals (NEU) receives the all clear from the US Food and Drug Administration (FDA) to commence phase two trials of its drug, NNZ-2591, on Phelan-McDermid syndrome (PMS) The trial will be conducted across four hospitals in U...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. At the start of trade on Frida...

Neuren Pharmaceuticals (ASX:NEU) has announced it has received approval from the Human Research Ethics Committee for its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome.

Neuren Pharmaceuticals (NEU) is granted ethics approval to move ahead with its phase two clinical trial for a drug to treat Angelman syndrome The Human Research Ethics Committee’s approval covers three sites in Australia for the clinical t...

Highlights Several ASX stocks have returned over 100% to shareholders in the past year. Such stocks are known as multibaggers. PLS, NEU, and CNB are a few big names which have given attractive returns. Despite the ASX...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Neuren Pharmaceuticals (ASX:NEU) sats it has received approval from the US FDA to proceed with the Phase 2 trial of NNZ-2591 in Angelman syndrome.

The S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBKD) is down 2.7% in the past year, but this one ASX biotech share could be a winner. The share has gained 188% in the past year, and 78% in the past six months. So which...

Neuren Pharmaceuticals (NEU) receives approval from the US Food and Drug Administration to proceed with the Phase 2 trial of NNZ-2591 in Angelman Syndrome The trial will be conducted at three hospitals across Australia, enrolling up to 20...

Highlights  Despite the ASX 200 trading on an uncertain note in the recent past, some stocks have given over 100% past year returns. The stocks with over 100% returns are called multibaggers stocks. PLS, UWL, NEU, AVR, and HXL are few...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. During his Australian Open quar...

Healthcare and life sciences expert Scott Power,who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The Australian Open has kicked o...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has more than doubled in less than a month. The biopharmaceutical company’s share price has gained 102%, shooting from $1.80 at the end of last month to $3.64 at the time of writing. E...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

While the S&P/ASX 200 Index (ASX: XJO) hasn’t provided much of a Santa rally this year, there are a number of ASX-listed shares that are still feeling merry this December. Taking a look at the data, 20 companies on the ASX with a mark...

Shareholders of Dimerix (ASX:DXB) got an early Christmas present with the company telling them its Phase 3 clinical trial testing its DMX-200 drug against COVID-19 pneumonia respiratory complications in Europe was on track. The study (REMAP...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It’s been a...

There were few major catalysts on Thursday, as the ASX traded flat in a relatively cruisy session following some solid gains this week. Broadly speaking, the ASX has tracked global stock markets higher after a rocky selloff last week that f...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Rett Syndrome is a rare genetic neurological disorder that affects the way the brain develops, causing a progressive loss of motor skills and speech. It’s a form of autism that primarily affects girls, or about one in every 10,000 to 15,000...

The ASX finished 0.67% higher, marking the best performance by the Australian bourse since early October. Almost all sectors finished higher with energy and tech – two sectors under siege in recent weeks – recording gains of 2.07% and 1.9%...

The share market climbed for a third day, adding to gains after the Reserve Bank appeared to open the door to a rate rise next year. The S&P/ASX 200 sealed its longest winning run in more than a month with an advance of 69 points or...

Highlights Newly listed companyRocketBoots declined as much as 17.5% on ASX debut. Zip Co surged more than 9% on strong business growth in November. Neuren Pharma spiked over 100% on positive trial results for its drug Trofinetide....

Highlights The ASX 200 traded higher by 0.6% by mid-session on Tuesday. Barring utilities and materials, all sectors traded in the green zone. Travel stocks surged on easing concerns about the Omicron variant. Newly listed company Ro...

Neuren Pharmaceuticals’ (NEU) partner has announced positive top-line results from a phase three study on Rett syndrome Acadia Pharmaceuticals’ phase three “Lavender” study evaluated the efficacy and safety of investigational drug trofinet...

The share market climbed to its highest in a week before tempering gains ahead of this afternoon’s Reserve Bank policy update. The S&P/ASX 200 trimmed a 67-point opening rally to 48 points or 0.66 per cent at mid-session. Travel s...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of positive phase three clinical trial results. Shares are currently swapping hands at $3.40 apiece, up exactly 100% from yesterday’s close. Let...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Neuren Pharmaceuticals (ASX:NEU) has reported that its partner for trofinetide in North America, Acadia Pharmaceuticals, has announced positive top-line results from a Phase 3 study.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Going into...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Neuren Pharmaceuticals (NEU) releases its September quarterly report, highlighting the progress with its upcoming clinical trials The phase three LAVENDER trial in people with Rett syndrome is progressing and top-line results are expected...

Neuren Pharmaceuticals (ASX:NEU) has announced it has received a Notice of Allowance from the US Patent and Trademark Office for a new patent that covers NNZ-2591 to treat autism.

Neuren Pharmaceuticals (NEU) receives a Notice of Allowance from the US Patent and Trademark Office for NNZ-2591 to treat autism The patent is titled “Bicyclic compounds and methods for their use in treating autism” and extends to July 20...

Neuren Pharmaceuticals (ASX:NEU) has raised $20 million through a placement of new shares to institutional and sophisticated investors at $2.05 per share.

ASX Capital Raise Roundup is a fortnightly look at ASX capital raisings. Investors were taken by surprise, in particular, with Thursday’s selloff. There were a number of explanations, but the biggest reasons resonating with us are seasonali...

Bankers for clinical-stage biotech company Neuren Pharmaceuticals will be pounding the virtual pavement on Friday morning.

Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has granted Orphan Drug designation to its NNZ-2591 for the treatment of Prader-Willi syndrome.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week The Healthcar...

Neuren Pharmaceuticals (ASX:NEU) today reported that its US partner for trofinetide, Acadia Pharmaceuticals, will be conducting a clinical trial in girls with diagnosed Rett syndrome.

Highlights  ASX-listed healthcare companies rarely fail to bring joy to the market participants, with a few of them providing outstanding returns in the last couple of months. Rhinomed, IDT Australia, and Prescient lead the way with ou...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

Summary Decmil (ASX:DCG) receives A$21 million civil balance of plant works contract dorsaVi (ASX:DVL) extends agreement with Medtronic Suvo (ASX:SUV) signs MOU and collaboration agreement with China-based Rezel The S&P/ASX2...

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

Neuren Pharmaceuticals (ASX: NEU) today announced that its US partner Acadia Pharmaceuticals has successfully completed enrolment in the LAVENDER Phase 3 trial of trofinetide in Rett syndrome.

Wall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Chair said he anticipates rates to increase by 2023. “Given this outlook and so long as inflation expectations remain well anchored at the 2%...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...